# Biolargo, Inc.: overview BLGO · OTC · CIK 880242 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/blgo.md) · [Financials](/companies/blgo/financials.md) · [Filings](/companies/blgo/filings.md) · [Insiders](/companies/blgo/insiders.md) Latest reported revenue: [$1.2m](/filings/0001437749-26-028023.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-028023). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [4,351](/filings/0001437749-25-035239.md) | [3,657 d](/filings/0001437749-26-006926.md) | [3,269](/filings/0001437749-26-017391.md) | [2,777](/filings/0001437749-26-028023.md) | [1,103](/filings/0001437749-25-035239.md) | [617 d](/filings/0001437749-26-006926.md) | [1,115](/filings/0001437749-26-017391.md) | [1,248](/filings/0001437749-26-028023.md) | | Gross margin | % | [39.6%](/filings/0001437749-25-035239.md) | [47.9% d](/filings/0001437749-26-006926.md) | [45.5%](/filings/0001437749-26-017391.md) | [51.2%](/filings/0001437749-26-028023.md) | [33.7%](/filings/0001437749-25-035239.md) | [20.7% d](/filings/0001437749-26-006926.md) | [41.1%](/filings/0001437749-26-017391.md) | [54.1%](/filings/0001437749-26-028023.md) | | Operating margin | % | [(24.4%)](/filings/0001437749-25-035239.md) | [(44.2%) d](/filings/0001437749-26-006926.md) | [(57.0%)](/filings/0001437749-26-017391.md) | [(64.9%)](/filings/0001437749-26-028023.md) | [(651.0%)](/filings/0001437749-25-035239.md) | [(650.1%) d](/filings/0001437749-26-006926.md) | [(287.4%)](/filings/0001437749-26-017391.md) | [(298.7%)](/filings/0001437749-26-028023.md) | | Net margin | % | [(24.4%)](/filings/0001437749-25-035239.md) | [(47.4%) d](/filings/0001437749-26-006926.md) | [(58.8%)](/filings/0001437749-26-017391.md) | [(67.8%)](/filings/0001437749-26-028023.md) | [(656.8%)](/filings/0001437749-25-035239.md) | [(671.3%) d](/filings/0001437749-26-006926.md) | [(305.4%)](/filings/0001437749-26-017391.md) | [(320.5%)](/filings/0001437749-26-028023.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.5](/filings/0001437749-23-008876.md) | [5.9](/filings/0001437749-24-010394.md) | [12.2](/filings/0001437749-24-010394.md) | [17.8](/filings/0001437749-26-006926.md) | [7.8](/filings/0001437749-26-006926.md) | | Gross margin | % | [43.6%](/filings/0001437749-23-008876.md) | [48.6%](/filings/0001437749-24-010394.md) | [50.3%](/filings/0001437749-25-010172.md) | [44.2%](/filings/0001437749-26-006926.md) | [43.9%](/filings/0001437749-26-006926.md) | | Operating margin | % | [(267.8%)](/filings/0001437749-23-008876.md) | [(91.6%)](/filings/0001437749-24-010394.md) | [(37.4%)](/filings/0001437749-25-010172.md) | [(24.4%)](/filings/0001437749-26-006926.md) | [(191.3%)](/filings/0001437749-26-006926.md) | | Net margin | % | [(272.4%)](/filings/0001437749-23-008876.md) | [(87.2%)](/filings/0001437749-24-010394.md) | [(38.0%)](/filings/0001437749-25-010172.md) | [(24.5%)](/filings/0001437749-26-006926.md) | [(195.6%)](/filings/0001437749-26-006926.md) | | Diluted EPS | $ per share | [(0.03)](/filings/0001437749-22-007726.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/blgo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FIRST AMERICAN TRUST, FSB](/funds/36066.md) | 2026-06-30 | $13.4k | 117,838 | | Unchanged | ## Recent filings [All 884 filings](/companies/blgo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 10:01 ET | [DEF 14A](/filings/0001437749-26-032868.md) | Proxy statement, period 2026-12-01 | 0001437749-26-032868 | | 2026-09-14 | 23:42 ET | [8-K/A](/filings/0001437749-26-030198.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-030198 | | 2026-09-11 | 14:38 ET | [8-K](/filings/0001437749-26-030124.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-030124 | | 2026-08-14 | 20:27 ET | [10-Q](/filings/0001437749-26-028023.md) | Quarterly report, period 2026-06-30 | 0001437749-26-028023 | | 2026-05-15 | 20:29 ET | [10-Q](/filings/0001437749-26-017391.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017391 | | 2026-05-06 | 10:02 ET | [8-K](/filings/0001437749-26-014996.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-014996 | | 2026-05-04 | 11:30 ET | [8-K](/filings/0001437749-26-014540.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-014540 | | 2026-04-30 | 20:02 ET | [10-K/A](/filings/0001437749-26-014184.md) | Annual report, amended, period 2025-12-31 | 0001437749-26-014184 | | 2026-04-09 | 18:50 ET | [S-1](/filings/0001437749-26-011880.md) | Registration statement | 0001437749-26-011880 | | 2026-04-09 | 18:35 ET | [S-1](/filings/0001437749-26-011875.md) | Registration statement | 0001437749-26-011875 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-006926.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/93f0a7d1-80fc-4886-9c37-2510b456508f) ## About the filer - CIK: 880242 - Tickers: BLGO - Exchange: OTC - SIC code: 2800 Chemicals & Allied Products - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.